Carlos Medina Mendez, MD
Retina Specialist · Sacramento, CANPI 1811218316
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $428,519 of the $547,507 with a category attached, or 78.3%. 18 manufacturers reported payments, led by Genentech USA, Inc. at 27.1% of the total. Reporting peaked in 2023 at $176,963 and has fallen 66.6% since, to $59,180 in 2025. Among retina specialist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 593 payments — averaging $923.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$149K
- Astellas Pharma US Inc$122K
- Biogen$94K
- Novartis$67K
- Apellis Pharmaceuticals, Inc.$55K
- Regeneron Healthcare Solutions, Inc.$37K
- plus $24K from 12 others
What the payments were for
- Consulting fees$33,5026%
- Speaking & faculty fees$428,51978%
- Travel & lodging$68,24912%
- Food & beverage$17,2183%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 158 | $148,613 |
| Astellas Pharma US Inc | 142 | $121,905 |
| Biogen | 87 | $94,466 |
| Novartis | 49 | $66,743 |
| Apellis Pharmaceuticals, Inc. | 39 | $55,333 |
| Regeneron Healthcare Solutions, Inc. | 44 | $36,843 |
| AbbVie(2 entities) | 17 | $7,739 |
| Regeneron | 7 | $5,787 |
| Genentech, Inc. | 6 | $4,526 |
| Alimera Sciences, Inc. | 21 | $2,811 |
| Eyepoint US, Inc. | 7 | $1,626 |
| Alcon | 6 | $449 |
| Amgen | 3 | $176 |
| Neurotech Pharmaceuticals, Inc. | 3 | $160 |
| Mallinckrodt Hospital Products Inc. | 1 | $144 |
| Coherus Oncology, Inc. | 1 | $125 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $42 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$547,507 in reported general payments places this provider in the 95th percentile of 187 retina specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 149 | $7,702 |
| Ketorolac Tromethamine | 82 | $1,810 |
| Brimonidine Tartrate | 38 | $1,057 |
| Ofloxacin | 74 | $906 |
| Latanoprost | 19 | $440 |
| Timolol Maleate | 31 | $195 |
| Dorzolamide Hcl | 11 | $180 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $168 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Sacramento
- Margaret ChangSacramento$197K
- Glenn YiuSacramento$146K
- Joel PearlmanSacramento$33K
- David TelanderSacramento$18K
- Maryam GhiassiSacramento$10K
- Dilsher DhootSanta Barbara$1.9M
- Ehsan RahimyStanford$1.5M
- Darius MoshfeghiPalo Alto$1.4M
- Nathan SteinleSanta Barbara$1.1M
- Roger GoldbergWalnut Creek$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.